According to the Zhitong Finance App, Xintai Healthcare (02291) announced interim results for the six months ended June 30, 2026. The group achieved total operating revenue of 310 million yuan, a year-on-year decrease of 5.94%; net profit attributable to shareholders of the parent company was 147 million yuan, a year-on-year decrease of 19.49%; and basic earnings per share were 0.4226 yuan.

The Group has set up four professional marketing teams for congenital heart disease, electrophysiology, valves and international trade to continue to expand sales channels and accelerate market penetration of domestic pipeline products through collection and implementation. The Group will consolidate and deepen exchanges and cooperation with research institutions, hospitals, clinicians and industry experts, continue to obtain clinical feedback and market information, optimize product design and production processes, enhance sales and service capabilities, and serve doctors and patients with better products and a more complete service system. While the penetration of various pipelines in the domestic market is accelerating, the Group is also simultaneously accelerating the strategic layout of overseas business.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.